Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
December 13, 2021 16:05 ET
|
Vaccitech (UK) Limited
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities.Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM...
Vaccitech, 만성 HBV에 대한 임상1b/2a상 시험에서 긍정적인 초기 효능성 분석 결과 도출
December 07, 2021 10:30 ET
|
Vaccitech (UK) Limited
만성B형간염(CHB) 환자를 대상으로 한 3개월 간의 HBV002 임상연구 마친 27명의 환자들의 초기 데이터를 보면, 표면 항원(HBsAg) 수치가 눈에 띄는 변화를 나타냈으며, 이는 다른 종류의 부스트(VTP-300)와 저용량 nivolumab을 투여 받은 그룹에서 두드러져 HBV002 임상연구는 현재 4개 환자 그룹 모집 중으로...
Vaccitech在慢性HBV的1b/2a期临床研究中报告了极具前景的中期疗效分析
December 07, 2021 10:30 ET
|
Vaccitech (UK) Limited
在慢性乙型肝炎(CHB)患者中,27名完成了3个月HBV002研究患者的中期数据表明,表面抗原(HBsAg)水平出现了显著变化,特别是在接受具有异源加强型(VTP-300)低剂量纳武单抗的人群中。 HBV002研究招募了4个组来探索初免-加强载体组合,其中包括MVA-HBV(初免)+ MVA-HBV(加强)、ChAdOx1-HBV(初免)+...
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
December 07, 2021 08:00 ET
|
Vaccitech (UK) Limited
Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the...
Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
November 24, 2021 09:20 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech의 VTP-300, 건강한 지원자 및 만성B형간염 환자 모두가 보유한 모든 표적 HBV 항원에 대해 우수한 내약성 및 T세포 유도 능력 보였다는 초기 결과 발표
November 12, 2021 21:55 ET
|
Vaccitech (UK) Limited
HBV001 및 HBV002 연구의 초기 데이터, 만성B형간염(CHB) 환자의 경우 이종 프라임-부스트 벡터 조합인 ChAdOx1-HBV + MVA-HBV (VTP-300)가 B형간염 바이러스 항원 표적에 대해 강력한 T세포 면역 반응 유도 ChAdOx-1-HBV (HBV001) 단독으로 쓰일 경우 건강한 지원자 및 CHB 환자에 대한 내약성 뛰어나;...
在中期分析中,Vaccitech的VTP-300对健康志愿者和慢性HBV感染患者中都具有良好耐受性,并可诱发T细胞对抗所有靶向HBV抗原
November 12, 2021 21:55 ET
|
Vaccitech (UK) Limited
HBV001和HBV002这两项研究的中期数据表明,在慢性乙型肝炎(CHB)患者中,ChAdOx1-HBV + MVA-HBV(VTP-300)的异源初免-加强载体组合诱发T细胞积极对抗靶向乙型肝炎病毒抗原。 仅ChAdOx-1-HBV(HBV001)在健康志愿者和CHB患者中表现出良好的耐受性;VTP-300(HBV002)在CHB患者中表现出良好的耐受性。 ...
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
November 12, 2021 08:00 ET
|
Vaccitech (UK) Limited
Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T...
Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 12, 2021 07:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview...
Vaccitech to Present at the Jefferies London Healthcare Conference
November 10, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...